999906259
Marinobufagenin as a Target for DIGIBIND in Preeclampsia
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT01328600/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–50 лет, только женщины. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 144 чел. во всех странах исследования.
- Центров в реестре: 3 в одном городе. Список — ниже на странице.
- Плановая дата окончания (07.2014) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 10 · невключение: 10
Критерии включения
- -INCLUSION CRITERIA:
- Pregnant women (18-50 years), 34-39 weeks of fetal gestational age with preeclampsia as defined by American College of ObGyn criteria. This definition of PE includes:
- diastolic blood pressure of at least 90 mm Hg or
- a systolic blood pressure of at least 140 mm Hg, or
- a rise in the former of at least 15 mm Hg or in the latter of 30 mm Hg on at least two occasions 6 hours or more apart,
- proteinuria (presence of 300 mg or more of protein in a 24-hour urine collection or a protein concentration of 1 g or more per liter in at least two random urine specimens collected 6 hours or more apart) or
- edema (a generalized accumulation of fluid of greater than 1+ pitting edema after 12 hours of bed rest or weight gain of 5 pounds or more in 1 week), or
- both, induced by pregnancy after the 20th week of gestation, and sometimes earlier.
- Healthy pregnant women (18-50 years) 34-39 weeks of fetal gestational age as control subjects.
- Decision of investigator to terminate pregnancy via cesarean section (patient is in need of immediate delivery as soon as clinically appropriate)
Критерии невключения
- Eclampsia, i.e., the occurrence of seizures not attributed to another cause during pregnancy
- Significant antecedent obstetrical problems that may interfere with study assessments or safe participation in the study
- Evidence of non-reassuring fetal well being
- Evidence of a lethal or life-threatening fetal anomaly
- Antecedent hypertension (hypertension secondary to preeclampsia, treated or untreated is allowed)
- Antecedent renal, hepatic, or autoimmune disease
- Medical or psychiatric disorders which are unstable or which might interfere with study assessments or safe participation in the study
- Evidence on medical history/evaluation of use of or need for digitalis-like products currently or in the future
- Serum creatinine greater than or equal to 1.5 mg/dl
- Inability to understand and provide informed consent
Источник: ClinicalTrials.gov, NCT01328600 · запись обновлена в реестре 9 декабря 2019.
Дизайн и результаты
Цель исследования
Background:
* Preeclampsia is a combination of high blood pressure and other potentially life-threatening symptoms. Preeclampsia occurs in up to 10% of pregnancies and is a main cause of maternal and fetal death worldwide. Treatment is often difficult, and so far there is no specific and effective therapy. Researchers have been studying the body systems that regulate blood pressure. They have also studied drugs that can control certain blood chemicals that constrict blood vessels and increase blood pressure.
* DIGIBIND, a drug that lowers blood pressure, has been used to treat pre-eclampsia. Marinobufagenin (MBG), a chemical in the blood that constricts blood vessels, has been shown to be involved in pre-eclampsia. But researchers are still not certain whether DIGIBIND can be used to specifically target MBG. Researchers want to find out whether DIGIBIND acts against MBG specifically. This information may help them to develop better drugs to block MBG and lower blood pressure in women with preeclampsia.
Objectives:
\- To study whether the blood pressure treatment drug DIGIBIND specifically acts on marinobufagenin levels in the blood of pregnant women.
Eligibility:
\- Women between 18 and 50 years of age who are 34 to 39 weeks pregnant and have preeclampsia.
Design:
* Participants will be screened with a physical examination, medical history, and blood and urine tests.
* Before delivery, participants will provide blood samples for testing and evaluation.
* Following delivery, participants will provide additional blood samples and samples of the placenta for testing and evaluation.
* No additional treatment, apart from the standard of care, will be provided as part of this protocol.
Где проходит
3 центра в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01328600 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.